Literature DB >> 27457763

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

Antoine Adenis1,2, Christelle de la Fouchardiere3, Bernard Paule4, Pascal Burtin5, David Tougeron6, Jennifer Wallet7, Louis-Marie Dourthe8, Pierre-Luc Etienne9, Laurent Mineur10, Stéphanie Clisant11, Jean-Marc Phelip12, Andrew Kramar7, Thierry Andre13.   

Abstract

Entities:  

Year:  2016        PMID: 27457763      PMCID: PMC4959046          DOI: 10.1186/s12885-016-2559-8

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


× No keyword cloud information.

Erratum

After publication of the original article [1], an error was noticed within the title: acronym “REBECCA” was erroneously written as “REBACCA”. The original article has now been updated with the correct title which can also be found above. The publisher would like to apologise for this error and for any inconvenience this may have caused.
  1 in total

1.  Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.

Authors:  Antoine Adenis; Christelle de la Fouchardiere; Bernard Paule; Pascal Burtin; David Tougeron; Jennifer Wallet; Louis-Marie Dourthe; Pierre-Luc Etienne; Laurent Mineur; Stéphanie Clisant; Jean-Marc Phelip; Andrew Kramar; Thierry Andre
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

  1 in total
  4 in total

1.  The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.

Authors:  Tony Reid; Bryan Oronsky; Nacer Abrouk; Scott Caroen; Pedro Cabrales
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 2.  Hydrogen Sulfide Biology and Its Role in Cancer.

Authors:  Saadullah Khattak; Mohd Ahmar Rauf; Nazeer Hussain Khan; Qian-Qian Zhang; Hao-Jie Chen; Pir Muhammad; Mohammad Azam Ansari; Mohammad N Alomary; Muhammad Jahangir; Chun-Yang Zhang; Xin-Ying Ji; Dong-Dong Wu
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

3.  Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?

Authors:  Qi Zhang; Qianqian Wang; Xicheng Wang; Jian Li; Lin Shen; Zhi Peng
Journal:  Int J Colorectal Dis       Date:  2019-12-17       Impact factor: 2.571

Review 4.  Biomarkers in Colorectal Cancer: Current Research and Future Prospects.

Authors:  Olorunseun O Ogunwobi; Fahad Mahmood; Akinfemi Akingboye
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.